Antifungal from F2G, Shionogi succeeds in Phase 3 study

Francesco Maria Lavino, F2G CEO (via website) June 18, 2026 12:01 AM EDT R&D An­ti­fun­gal from F2G, Sh­iono­gi suc­ceeds in Phase 3 study Max Gelman Senior Editor F2G and Sh­iono­gi re­leased pos­i­tive Phase 3 da­ta on Thurs­day morn­ing, giv­ing the com­pa­nies a po­ten­tial­ly clear path to ap­proval for their an­ti­fun­gal drug. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER